Recursion Pharmaceuticals

  • The company develops a phenotypic, high-throughput drug-screening platform to identify drug targets for genetic diseases, inflammatory diseases, immunologic diseases, infectious diseases, and more
  • The value of the company's platform lies in its flexibility and scalability (Chris said the platfo...

This item has been archived in line with our efforts to keep our content relevant and up to date for our readership. For further assistance, please contact your Customer Success Manager or email Thank you!

Related Research

Amalgam Rx

Company Profile | December 13, 2021

Amalgam Rx is a developer of a software‑as‑a‑service (SaaS)‑based technology platform that enables the development, deployment, and scaling of digital therapeutics and health service applications such as electronic health record (EHR) integration, clinical decision support, and clinical trial ... To read more, click here.

Regulus Therapeutics

Company Profile | December 01, 2021

Regulus Therapeutics was created as a joint venture between Alnylam Pharmaceuticals, an RNAi therapeutics company, and Isis Pharmaceuticals (now known as Ionis Pharmaceuticals), a company focused on anti‑sense technologies and therapeutics, in 2007 Regulus Therapeutics is focused on the ... Not part of subscription

Pfizer partnering with Alex Therapeutics to develop nicotine-addiction DTx

News Commentary | February 08, 2022

Pfizer has partnered with Stockholm‑based DTx (digital therapeutics) maker Alex Therapeutics to deploy artificial intelligence (AI)‑based digital therapeutics. The Alex DTx platform combines cognitive‑based therapy and acceptance and commitment therapy with AI to offer personalized treatment plans. ... Not part of subscription